"Resectins are an enormous opportunity for the development of new medicines, and it is a privilege to be a part of such promising new science. I am excited to work along side such a talented and committed management team, backed by experienced investors and successful scientific founders," said Dr. Johnson. "Overlooked by the human genomics efforts, and with activities that are differentiated from existing therapies and common pharmaceutical discovery targets, the resectins represent a wealth of completely novel product opportunities. The establishment of a select set of strategic partnerships will be a significant catalyst for aTyr's growth, and will enable the company to fully capture the value underlying aTyr's novel source of the resectin human proteins and drug targets."
About aTyr Pharma
aTyr Pharma engages in the generation of innovative therapeutics based on a new class of naturally occurring human proteins. These proteins, called resectins, modulate extracellular signaling pathways in a variety of biological processes. Resectins, previously overlooked by genomic efforts due to their hidden intra-protein location in ancient aminoacyl tRNA synthetase genes, have recently been discovered by aTyr, which is leading to connections in human physiology and pathophysiology ranging from inflammation to metabolic disease to peripheral neuropathy to blood disorders. Resectin biology is distinct from currently known pathways and pharmaceutical targets and thus represents breakthrough opportunities for novel thera
|SOURCE aTyr Pharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved